In September, we announced our collaboration with Musella Foundation, xCures, and Oncoceutics to help patients access ONC201, a potential new treatment for a type of brain tumor known as diffuse intrinsic pontine glioma (DIPG), as well as other gliomas with a genetic mutation known as H3 K27M.
Since then, several news stories have reported promising developments for ONC201. Check out the coverage:
Atrium Health: “Finding hope in the face of brain cancer: After being diagnosed with a brain tumor, Amanda’s future was uncertain. But participating in a Phase 2 clinical trial has given her more time, more hope and a new mission.” (Also covered on WSOC-TV)
Critical to the collaboration is $1M in funding from The Musella Foundation, Michael Mosier Defeat DIPG Foundation and The Cure Starts Now Foundation. Cancer Commons and xCures will contribute additional resources to the success of the collaboration. “The Musella Foundation, Michael Mosier Defeat DIPG Foundation and The Cures Starts Now Foundation are excited to partner with Oncoceutics to translate a new molecularly-targeted therapeutic concept,” said Al Musella, DPM, President and Founder of the Musella Foundation.
Due to the tumor location within the midline region of the brain, as well as patients with a specific mutation called H3 K27M, patients often have significant neurological symptoms from their disease. There are no proven therapeutic options other than palliative radiotherapy. However, emerging clinical results have shown that some patients with H3 K27M-mutant glioma treated with single agent ONC201 have had their tumor stabilize or shrink and have had improvements in neurological symptoms, such as paralyses of peripheral and cranial nerves. Continue reading…
“Robert H. Lurie Children’s Hospital of Chicago have revealed new insight into how the most deadly pediatric brain tumor, diffuse intrinsic pontine glioma (DIPG), may develop. They also have identified a compound that targets the ‘on’ switch for cancer-promoting genes, which resulted in shrinking tumor size and increased survival in an animal model of DIPG. Preparations for a clinical trial at Lurie Children’s are now under way.”